Biotechnology News and Research

RSS

Selcia announces drug discovery collaboration agreement with Gilead Sciences

Selcia Limited, a leading contract research organisation, today announced a drug discovery collaboration agreement with Gilead Sciences, Inc. (Foster City, California).

29 Nov 2010

Pfizer, Protalix announce marketing authorization submission in Europe for taliglucerase alfa

Pfizer Inc. and Protalix BioTherapeutics, Inc. today announced the submission of a Marketing Authorization Application to the European Medicines Agency for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD)for the treatment of Gaucher disease. Taliglucerase alfa was granted Orphan Designation by the European Commission for the treatment of Gaucher disease on March 23, 2010.

29 Nov 2010

Sigma-Aldrich enters distribution agreement with Nanosys

Sigma-Aldrich today announced a distribution agreement with Nanosys, Inc., an advanced materials architect. Under the agreement, Sigma-Aldrich, through its Aldrich Materials Science business, is now distributing Nanosys-created silicon nanowires to the global scientific research community for the development of new applications in technologies such as solid-state lighting, electronics and energy storage.

29 Nov 2010

Thomson Reuters announces acquisition of GeneGo

Thomson Reuters today announced that it has acquired GeneGo, a leading provider of biology and disease information, analytics, and decision support solutions for pharmaceutical research and development.

29 Nov 2010

New irreversible covalent approach to inhibit viral protease

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of a viral protease using a targeted covalent drug.

28 Nov 2010

Pharma enhances its focus on Asia-Pacific partnerships

While the Japanese market still dominates deal activities in the Asia-Pacific (APAC) region, companies and research institutes in emerging APAC countries have recently been attracting high calibre collaborators, according to the latest analysis by Datamonitor.

28 Nov 2010

CQDM and Alsace BioValley enter long term research collaboration

Alsace BioValley, a French competitive health cluster dedicated to therapeutic innovation and CQDM (Québec Consortium for Drug Discovery) sign in Paris today an agreement on a bilateral partnership for the benefit of Alsatian and Quebec research centers and industries in the life sciences and health sector.

26 Nov 2010

Medicago, Genopole expand collaboration

Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced an extension to its partnering agreement of July 2009 with Genopole®. Medicago and Genopole® will also work towards the creation a laboratory for research on vaccine and antibody targets of interest for France in terms of public health and biodefense.

26 Nov 2010

Genzyme meets FDA consent decree by ending fill/finish activities in Allston plant

Genzyme Corporation announced today that the company has ended fill/finish operations within its Allston plant for products sold in the United States, as required by the FDA consent decree.

25 Nov 2010

Advaxis initiates ADXS11-001 clinical trial for cervix cancer

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has begun dosing patients in its 110 patient clinical trial of ADXS11-001 for the treatment of cervix cancer in women for whom cytotoxic treatment has failed.

24 Nov 2010

NIH expands genetic and clinical research database to provide access to digital study images

The National Institutes of Health has expanded a genetic and clinical research database to give researchers access to the first digital study images.

24 Nov 2010

Massachusetts makes drug and medical device company payments public

The Boston Globe: "Massachusetts health officials published online yesterday the most comprehensive state database in the country listing payments drug companies and medical device makers have made to doctors, nurses, pharmacists, hospitals, and other health care providers. The report lists $35.7 million in payments from hundreds of companies for the six months between July 1 and Dec. 31, 2009 … About half of that money, or $16.4 million, went to physicians. This is the first time Massachusetts has made such information public.

24 Nov 2010

Vertex submits NDA for telaprevir for treating hepatitis C

Vertex Pharmaceuticals Incorporated announced that it has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for telaprevir, Vertex's investigational treatment for people with hepatitis C.

23 Nov 2010

ShangPharma third quarter net revenue increases 16.6% to $23.1 million

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its third quarter ended September 30, 2010.

23 Nov 2010

DiaGenic ASA announces subsequent offering of 60,000,000 shares

Reference is made to the stock exchange notice dated 3 November 2010 and the prospectus dated 2 November 2010 regarding a subsequent offering of up to 60,000,000 offer shares in DiaGenic ASA each with a nominal value of NOK 0.05, at a subscription price of NOK 0.50 per share with subscription rights for shareholders of the Company as of 6 October 2010, except shareholders who were allocated shares in the private placement completed on 6 October 2010.

23 Nov 2010

USPTO, EPO issue key patents for Tekmira's LNP technology

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today that the United States Patent & Trademark Office (USPTO) and the European Patent Office (EPO) have issued key patents covering elements of Tekmira's leading lipid nanoparticle (LNP) technology, which is used to deliver nucleic acid therapeutics, including small interfering RNA (siRNA).

23 Nov 2010

AADR Fall Focused Symposium highlights fast-moving field of Salivary Diagnostics

The American Association for Dental Research (AADR) held its 3rd Fall Focused Symposium on November 12-13, in the Washington, DC, area. This year, the theme was the fast-moving field of Salivary Diagnostics, with a focus on Scientific & Clinical Frontiers.

23 Nov 2010

Evotec to collaborate with Merck on neurological disease drug discovery program

Evotec AG today announced that it has signed within the "NEU²-Consortium" framework and partially funded by the Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung - BMBF), an agreement with Merck KGaA, Darmstadt, Germany, to develop pre-clinical candidates for an undisclosed neurological disease. Evotec will provide drug discovery expertise covering in vitro biology, medicinal chemistry and in vitro and in vivo pharmacology.

23 Nov 2010

New findings shed light on people's response to daylight and biological clock

Fresh insight into how biological clocks adjust to having less sunlight in the winter could help us better understand the impact of jet lag and shift work.

23 Nov 2010

DoD awards Regenicin and Lonza $18 million to develop PermaDerm for severe burns

The U.S. Department of Defense recently awarded more than $18 million in funding to a unit of Lonza Group, Ltd. for the development and commercialization of the therapeutic candidate, PermaDerm™ for the treatment of severe burns among U.S. troops and civilians. The funding was announced at a conference celebrating advancements in regenerative medicine on November 9th in Walkersville, MD.

23 Nov 2010